Characterised disease state plasma

The earlier a disease can be detected, the sooner therapy can start. In an infection, the earliest immune response is IgM, but it also tails off as IgG antibodies take up the challenge.

IgM detection would offer the earliest indication of disease; however, creating diagnostic devices for IgM is challenging due to a lack of control material, since the high levels of IgM decline relatively quickly, offering only a short window to identify potential donors for disease state plasma. Individual responses can vary, and the levels of IgM in each sample need to be characterised before use, which is time-consuming, costly, and also uses up valuable samples.

IgM for established diseases such as measles, CMV, and EBV are available, as well as some emerging diseases that may become more prevalent as global climate changes take hold, such as dengue and Zika. For some viruses, such as RSV, IgA antibodies may also be of clinical interest.

B Cell Design offers monoclonal antibodies with human Fc as the best alternative to characterised disease state plasma. These antibodies can be used to develop IVD tests such as ELISA and lateral flow and are available to match your research schedule’s needs.

This solution offers consistent raw materials for immunoassay controls for industrial batch-to-batch reproducibility or research needs. With consistent signal generation across batches, the human Fc mAbs can be used to check antigen absorption and assay performance, reducing the need for re-validations of control materials and saving time & money!

Their range covers IgM, IgG, IgA, and IgE for a number of infectious agents, allergens, and autoimmune antigens, but they also offer custom manufacture if you can’t find what you’re looking for off the shelf!

For researchers working on lateral flow, why not check out the range of Gold particles and kits from nanoComposix, including a Material starter kit for lateral flow!